Project Size: £100,000 to £1 million
SBRI's Advancements in Dementia Biomarker Technologies 2023: Propelling Transformative Dementia Therapies
The Opportunity Unfolded
The Small Business Research Initiative (SBRI), funded by Innovate UK, is excited to announce the opening of applications for its Advancements in Dementia Biomarker Technologies competition on Monday 24 July 2023. With a closing date on Monday 4 September 2023 at 11 am, the competition offers a share of up to £6 million for the development and enhancement of platform technologies for dementia therapies.
Objective of the Competition
The competition seeks to stimulate:
The development or repurposing of platform technologies which can be utilised as clinical tools, thereby fostering the development of transformative therapies for dementia. The initiative particularly encourages projects that demonstrate significant innovation in the detection of dementia biomarkers. Such advances will support the goals of the UK government’s Dame Barbara Windsor dementia mission.
Applicants must be UK-registered businesses of any size, including research and technology organisations (RTOs). Projects must involve at least one micro, small, or medium-sized enterprise (SME). If the lead organisation is an RTO, it must collaborate with two businesses, including one SME. Academic institutions are ineligible to lead or work alone.
Proposals should clearly articulate how the project will advance the detection of dementia biomarkers and contribute to transformative dementia therapies. Projects need to commence by 1st February 2024 and conclude by 31st October 2024. Projects are to be carried out entirely within the UK and the results exploited in or from the UK. A total grant request must not exceed £250,000.
Funding and Support:
Projects can request total costs between £100,000 and £1 million, inclusive of VAT. Funding will be provided under the procurement category.
By entering this competition, you are participating in a competitive process. The competition concludes at 11 am UK time on the closing date.
Successful applicants will need to demonstrate a clear route to commercialisation and show significant potential to benefit the UK economy.
Ready to Propel Advancements in Dementia Therapies?
If your organisation is prepared to drive innovation in dementia biomarker technologies, reach out to us at Inventya on 01925 506 100 or at email@example.com. We look forward to supporting your breakthrough endeavours.